Survey NEN / Inquérito NEN
| Autor: | Carla Andressa Rodrigues Dias Fleury de Lima, Renata D'Alpino Peixoto, Rui F. Weschenfelder, Gabriel Prolla, Juliana F Rego, Duilio Rocha, Marcela Crosara, Gustavo Fernandes, Paulo M Hoff, Aline Chaves Andrade, Anelisa K. Coutinho, Rachel P. Riechelmann |
|---|---|
| Jazyk: | portugalština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Brazilian Journal of Health Review; Vol. 5 No. 4 (2022); 12017-12029 Brazilian Journal of Health Review; v. 5 n. 4 (2022); 12017-12029 Brazilian Journal of Health Review Federação das Indústrias do Estado do Paraná (FIEP) instacron:BJRH |
| ISSN: | 2595-6825 |
| Popis: | Introduction: Although new treatments and diagnostic methods for Neuroendocrine Neoplasms (NEN) have been introduced, the level of access to them needs somehow to be further investigated. Objectives: to understand the aspects that influence the access to the diagnosis, follow-up and treatment of patients with NEN in Brazil. Methods: This is a cross-sectional electronic survey conducted by the Brazilian Group of Gastrointestinal Tumors (GTG) and containing sixteen questions sent to Brazilian Oncologists via messaging app, aiming to identify access profiles to diagnostic and follow-up tests among patients with NEN, in addition to proven effective treatments in the Public and Private Brazilian Health Care System. Descriptive analysis was used to report the outcomes.Results: The survey was carried out with 201 Oncologists. Since (31.8%) of the Oncologists responded that they have been trained for more than 15 years and have been working with clinical practice within the scope of the Brazilian National Health System and/or the Private Health Care. For follow-up, the most requested marker was Chromogranin A (39%). Regarding diagnosis, 35.8% of the 201 participants claim to ask for a slide review in their clinical practice, and their access to tomography and resonance (58%). When contextualizing the performance of PET Scan with Gallium 68, it is available in (15%), but a significant percentage did not have access in the Brazilian National Health System Service, corresponding to (95%). Subgroup analysis revealed statistically significant differences in the availability of Somatostatin Analogue, being offered in 56% in the Brazilian National Health System and 84% in the Private Health Care (p < 0.05). Conclusion: This is the first Brazilian research that evaluated access to diagnostic and therapeutic tools in the Brazilian scenario, showing important access limitations, especially in the public sector. In view of the results presented, these restrictions can lead to unfavorable clinical outcomes in patients with NEN in Brazil. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|